nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

04.05.2018 | Original Article – Clinical Oncology

Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma

verfasst von: Kai Wang, Xiao Qu, Shaorui Liu, Xudong Yang, Fenglong Bie, Yu Wang, Cuicui Huang, Jiajun Du

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

F-box proteins, as components of the Skp1-Cullin 1-F-box protein (SCF) E3 ubiquitin ligase, can specifically bind to substrates and regulate multiple tumor behaviors. However, the role of F-box proteins in squamous-cell lung carcinoma (SqCLC) has not been established.

Methods

We identified the differentially expressed F-box protein-encoding genes in SqCLC by analyzing data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Prognosis data were evaluated using the Kaplan–Meier (KM) plotter website. The FBXO5 and FBXO45 mRNA levels were analyzed by real time RT-PCR. The impact of the inhibition of these genes with si-RNA on apoptosis and migration was also investigated.

Results

The FBXO45 and FBXO5 genes were significantly up-regulated in SqCLC compared with normal lung (p values = 0.002 and 0.025, respectively). FBXO45 was significantly elevated in each tumorigenic step, including dysplasia, in situ and SqCLC. The RT-PCR analysis results showed that FBXO5 and FBXO45 were elevated in cancer tissues (p values = 0.024 and 0.004, respectively). Overexpression of FBXO5 and FBXO45 was associated with shorter overall survival (OS) in the SqCLC patients from the K–M plotter database [FBXO5 HR: 1.53 (1.03–2.28), p = 0.036]; [FBXO45 HR: 1.47 (1.03–2.08), p = 0.030]. The GO and KEGG pathway analysis showed that FBXO5 and FBXO45 were associated with cell cycle and adhesion, respectively. Knockdown of FBXO5 leads to increased apoptosis, while knockdown of FBXO45 facilitates the process of epithelial–mesenchymal transition (EMT).

Conclusions

Our results provide evidence that FBXO45 and FBXO5 may play a key role in tumorigenesis and prognosis of SqCLC.

Nur mit Berechtigung zugänglich

Abshire CF, Carroll JL, Dragoi AM (2016) FLASH protects ZEB1 from degradation and supports cancer cells’ epithelial-to-mesenchymal transition. Oncogenesis 5:e254. https://doi.org/10.1038/oncsis.2016.55 CrossRefPubMedPubMedCentral

Amm I, Sommer T, Wolf DH (2014) Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochimica et Biophysica Acta 1843:182–196. https://doi.org/10.1016/j.bbamcr.2013.06.031 CrossRefPubMed

Barbash O, Diehl JA (2008) SCF (Fbx4/alphaB-crystallin) E3 ligase: when one is not enough. Cell Cycle 7:2983–2986. https://doi.org/10.4161/cc.7.19.6775 CrossRefPubMed

Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519–525 https://doi.org/10.1038/nature11404 CrossRef

Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRefPubMed

Cheng Y, Li G (2012) Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev 31:75–87. https://doi.org/10.1007/s10555-011-9330-z CrossRefPubMed

Choi M et al (2017) Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol 28:83–89. https://doi.org/10.1093/annonc/mdw437 CrossRefPubMed

Chung FZ, Sahasrabuddhe AA, Ma K, Chen X, Basrur V, Lim MS, Elenitoba-Johnson KS (2014) Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin and promotes neuronal differentiation. J Biol Chem 289:28448–28459. https://doi.org/10.1074/jbc.M114.561241 CrossRefPubMedPubMedCentral

Davis RJ, Welcker M, Clurman BE (2014) Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell 26:455–464. https://doi.org/10.1016/j.ccell.2014.09.013 CrossRefPubMedPubMedCentral

Deng W, Wang Y, Liu Z, Cheng H, Xue Y (2014) HemI: a toolkit for illustrating heatmaps. PloS One 9:e111988. https://doi.org/10.1371/journal.pone.0111988 CrossRefPubMedPubMedCentral

Di Fiore B, Pines J (2008) Defining the role of Emi1 in the DNA replication-segregation cycle. Chromosoma 117:333–338. https://doi.org/10.1007/s00412-008-0152-x CrossRefPubMed

Diaz VM, de Herreros AG (2016) F-box proteins: keeping the epithelial-to-mesenchymal transition (EMT) in check. Semin Cancer Biol 36:71–79. https://doi.org/10.1016/j.semcancer.2015.10.003 CrossRefPubMed

Duan S et al (2012) FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481:90–93. https://doi.org/10.1038/nature10688 CrossRefPubMedPubMedCentral

Edelmann MJ, Nicholson B, Kessler BM (2011) Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 13:e35. https://doi.org/10.1017/S1462399411002031 CrossRefPubMedPubMedCentral

Ettinger DS et al (2017) Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:504–535CrossRefPubMed

Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438–449. https://doi.org/10.1038/nrc2396 CrossRefPubMedPubMedCentral

Gao M, Karin M (2005) Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell 19:581–593. https://doi.org/10.1016/j.molcel.2005.08.017 CrossRefPubMed

Gao J et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https://doi.org/10.1126/scisignal.2004088 CrossRefPubMedPubMedCentral

Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PloS One 8:e82241. https://doi.org/10.1371/journal.pone.0082241 CrossRefPubMedPubMedCentral

Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KSJ, Rangnekar VM (2017) A naturally generated decoy of the prostate apoptosis response-4 protein overcomes therapy resistance in tumors. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-16-1970 PubMedCrossRefPubMedCentral

Heo J, Eki R, Abbas T (2016) Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol 36:33–51. https://doi.org/10.1016/j.semcancer.2015.09.015 CrossRefPubMed

Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57CrossRef

Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13. https://doi.org/10.1093/nar/gkn923 CrossRefPubMed

Langer CJ et al (2016) Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment. J Thorac Oncol 11:2066–2081. https://doi.org/10.1016/j.jtho.2016.08.138 CrossRefPubMed

Lee J, Kim JA, Barbier V, Fotedar A, Fotedar R (2009) DNA damage triggers p21WAF1-dependent Emi1 down-regulation that maintains G2 arrest. Mol Biol Cell 20:1891–1902. https://doi.org/10.1091/mbc.E08-08-0818 CrossRefPubMedPubMedCentral

Liao SY et al (2017) CK1δ/GSK3β/FBXW7α axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression. Oncogene. https://doi.org/10.1038/onc.2017.168 CrossRefPubMedPubMedCentral

Lu Y et al (2012) The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. J Biol Chem 287:41014–41022. https://doi.org/10.1074/jbc.M112.407106 CrossRefPubMedPubMedCentral

Lu Y, Lee BH, King RW, Finley D, Kirschner MW (2015) Substrate degradation by the proteasome: a single-molecule kinetic analysis. Science 348:1250834. https://doi.org/10.1126/science.1250834 CrossRefPubMedPubMedCentral

Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G (2009) The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 28:3157–3166. https://doi.org/10.1038/onc.2009.177 CrossRefPubMed

Randle SJ, Laman H (2016) F-box protein interactions with the hallmark pathways in cancer. Semin Cancer Biol 36:3–17. https://doi.org/10.1016/j.semcancer.2015.09.013 CrossRefPubMed

Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK (2001) Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell 105:645–655CrossRefPubMed

Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R (2015) Squamousness: next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle 14:2355–2361. https://doi.org/10.1080/15384101.2015.1053669 CrossRefPubMedPubMedCentral

Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. https://doi.org/10.1038/nrclinonc.2017.44 PubMedPubMedCentralCrossRef

Shimizu N et al (2013) Selective enhancing effect of early mitotic inhibitor 1 (Emi1) depletion on the sensitivity of doxorubicin or X-ray treatment in human cancer cells. J Biol Chem 288:17238–17252. https://doi.org/10.1074/jbc.M112.446351 CrossRefPubMedPubMedCentral

Socinski MA et al (2016) Clinicopathologic features of advanced squamous NSCLC. J Thorac Oncol 11:1411–1422. https://doi.org/10.1016/j.jtho.2016.05.024 CrossRefPubMed

Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550. https://doi.org/10.1073/pnas.0506580102 CrossRefPubMed

Szklarczyk D et al (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:D447–D452 https://doi.org/10.1093/nar/gku1003 CrossRef

Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM (2016) Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol 36:18–32. https://doi.org/10.1016/j.semcancer.2015.09.008 CrossRefPubMed

Uhlen M et al (2017) A pathology atlas of the human cancer ranscriptome. Science. https://doi.org/10.1126/science.aan2507 CrossRefPubMed

Vaidyanathan S, Cato K, Tang L, Pavey S, Haass NK, Gabrielli BG, Duijf PH (2016) In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene 35:5446–5455. https://doi.org/10.1038/onc.2016.94 CrossRefPubMed

Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14:233–247. https://doi.org/10.1038/nrc3700 CrossRefPubMedPubMedCentral

Wang K et al (2016) The impact of ramucirumab on survival in patients with advanced solid tumors: a systematic review and meta-analysis of randomized II/III controlled trials. Clin Drug Investig 36:27–39CrossRefPubMed

Xu M et al (2015) Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transition-inducing transcription factors. Oncotarget 6:979–994. https://doi.org/10.18632/oncotarget.2825 PubMedCrossRef

Xu W, Taranets L, Popov N (2016) Regulating Fbw7 on the road to cancer. Semin Cancer Biol 36:62–70. https://doi.org/10.1016/j.semcancer.2015.09.005 CrossRefPubMed

Yokobori T et al (2014) FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs Molecular cancer research. MCR 12:32–37. https://doi.org/10.1158/1541-7786.MCR-13-0341 CrossRefPubMed

Titel: Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma
verfasst von: Kai Wang
Xiao Qu
Shaorui Liu
Xudong Yang
Fenglong Bie
Yu Wang
Cuicui Huang
Jiajun Du
Publikationsdatum: 04.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2653-1

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Relationship between TNF-α −1031T/C gene polymorphism, plasma level of TNF-α, and risk of cachexia in head and neck cancer patients

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients

Emerging strategies in BRCA-positive pancreatic cancer

Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model

Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie